Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Last trade$1.78
Day change-$0.08 (-4.30%)
Day range$1.49 – $1.81
Volume972,138
Market cap$61M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$60.87M
Price / earnings
—
Price / book
-2.86×
Price / sales
36.45×
EV / sales
25.82×
EV / EBITDA
-1.1×
Profitability
Earnings per share
-$1.51
Return on assets
-167.64%
Return on equity
231.74%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
2×
Quick ratio
1.98×
Cash ratio
1.73×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$30.88M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IMDX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Revenue
$239K
$32K
$1.14M
$260K
$518K
Cost of revenue
$82K
$17K
$643K
$121K
$180K
Gross profit
$157K
$15K
$496K
$139K
$338K
Selling, general and administrative
$4.79M
$5.39M
$4.62M
$3.93M
$4.11M
Research and development
$4.49M
$4.95M
$5.83M
$3.88M
$3.27M
Total operating expenses
$11.56M
$10.35M
$23.93M
$11.19M
$10.18M
Operating income
-$11.4M
-$10.33M
-$23.44M
-$11.05M
-$9.84M
Interest expense
-$20K
$0
-$26K
-$29K
-$25K
Income before taxes
-$11.26M
-$4.29M
-$22.96M
-$10.85M
-$9.74M
Income taxes
$0
$0
$0
$0
$0
Net income
-$11.26M
-$4.29M
-$22.96M
-$10.85M
-$9.74M
Net income attributable to common shareholders
-$11.26M
-$4.29M
-$22.96M
-$10.85M
-$9.74M
EBITDA
-$10.74M
-$9.7M
-$8.27M
-$10.46M
-$9.28M
Basic earnings per share
-$0.31
-$0.12
-$0.71
-$0.34
-$0.30
Diluted earnings per share
-$0.31
-$0.12
-$0.71
-$0.34
-$0.30
Recent news
Company coverage with links to the original publishers.
Medicare issued a favorable local coverage determination (LCD) for donor-derived cell-free DNA (dd-cfDNA) testing, expanding reimbursement for transplant organ monitoring. The policy increases surveillance testing frequencies across kidney and heart transplants compared to previous guidelines, supporting iMDx's commercial strategy for in-house testing kits. The company's flagship GraftAssureCore test is reimbursed at $2,753 per result, while GraftAssureDx awaits FDA marketing authorization.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.